Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cefuroxime generics dispute

Executive Summary

Apotex' request to preliminarily enjoin Ranbaxy from marketing generic versions of GlaxoSmithKline's Ceftin (cefuroxime axetil) rejected by a D.C. appeals court Nov. 26. The Federal Circuit upheld a ruling that Apotex failed to show a reasonable likelihood of success on the merits of its claim that Ranbaxy's manufacturing process infringes an Apotex patent under the doctrine of equivalents. Ranbaxy was the first Ceftin generic on the market in early 2002; Apotex' entry was delayed until July 2003 (1"The Pink Sheet" May 12, 2003, In Brief). A trial on GSK's patent infringement claims against Ranbaxy was held in Trenton, N.J. federal court during the summer; a decision is pending...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

PS042905

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel